3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Recurrence
2
Carcinoma, Non-Small-Cell Lung
2
Virus Diseases
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Influenza, Human
1
Head and Neck Neoplasms
1
Ganglioneuroblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
B-cell Malignancies
1
Interventions
Temozolomide
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Cyclophosphamide
6
Topotecan
5
Isotretinoin
5
Irinotecan
5
3-Iodobenzylguanidine
4
naxitamab
3
dinutuximab
3
Vincristine
3
venetoclax
2
trametinib
2
ribociclib
2
racotumomab
2
omburtamab I-131
2
fludarabine
2
dabrafenib
2
3-fluorobenzylguanidine
2
sonidegib
1
robatumumab
1
regorafenib
1
plerixafor
1
palbociclib
1
niraparib
1
molibresib
1
lorlatinib
1
entrectinib
1
dostarlimab
1
copanlisib
1
ceritinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroblastoma
×
Influenza Vaccines
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled